Based on the Aclaris Therapeutics Inc stock forecast from 5 analysts, the average analyst target price for Aclaris Therapeutics Inc is USD 7.40 over the next 12 months. Aclaris Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aclaris Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Aclaris Therapeutics Inc’s stock price was USD 1.27. Aclaris Therapeutics Inc’s stock price has changed by +11.40% over the past week, -25.29% over the past month and +8.55% over the last year.
No recent analyst target price found for Aclaris Therapeutics Inc
No recent average analyst rating found for Aclaris Therapeutics Inc
Company Overview Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Read Less
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is inv...Read More
Frequently Asked Questions About Aclaris Therapeutics Inc (ACRS) Stock
Based on ratings from 5 analysts Aclaris Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ACRS's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for ACRS is USD 7.40 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on ACRS's stock to indicate if its overvalued.
The last closing price of ACRS's stock was USD 1.27.
The most recent market capitalization for ACRS is USD 0.15B.
Based on targets from 5 analysts, the average taret price for ACRS is projected at USD 7.40 over the next 12 months.
This means that ACRS's stock price may go up by +482.68% over the next 12 months.
We can't find any ETFs which contains Aclaris Therapeutics Inc's stock.
As per our most recent records Aclaris Therapeutics Inc has 61 Employees.
Aclaris Therapeutics Inc's registered address is 701 Lee Road, Wayne, PA, United States, 19087.
You can get more information about it from Aclaris Therapeutics Inc's website at https://www.aclaristx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Aclaris Therapeutics Inc (ACRS) Stock
Based on ratings from 5 analysts Aclaris Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ACRS's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for ACRS is USD 7.40 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on ACRS's stock to indicate if its overvalued.
The last closing price of ACRS's stock was USD 1.27.
The most recent market capitalization for ACRS is USD 0.15B.
Based on targets from 5 analysts, the average taret price for ACRS is projected at USD 7.40 over the next 12 months.
This means that ACRS's stock price may go up by +482.68% over the next 12 months.
We can't find any ETFs which contains Aclaris Therapeutics Inc's stock.
As per our most recent records Aclaris Therapeutics Inc has 61 Employees.
Aclaris Therapeutics Inc's registered address is 701 Lee Road, Wayne, PA, United States, 19087.
You can get more information about it from Aclaris Therapeutics Inc's website at https://www.aclaristx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ACRS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
